From Preclinical Testing to Proof of Concept in Humans

Aim

Prioritising areas of therapeutic interest and target product profile. Principles for target identification, understanding of combinatorial chemistry and drugability of new compounds. Exploring possible new drugs by means of preclinical safety and efficacy testing. The choice and the predictive value of animal testing for toxicity data as well as the principles of ADME, possibilities and opportunities of computer assisted modelling on the way to proof of concept. Procedures and databases for pharmacovigilance and pharmacoepidemiology surveillance. Pharmaceutical engineering and choice of formulation.

Location & Organization

Organizer

ECPM - European Center of Pharmaceutical Medicine, University of Basel

Faculty / Teachers

Geo Adam, F. Hoffmann-La Roche AG, Basel, Rainer Alex, F. Hoffmann - La Roche Ltd, Basel, Philip Bentley, Novartis Pharmaceuticals Corp., East Hanover, NJ, Adam F. Cohen, CHDR, Leiden, Michael Collis, Consultant, London, Julian Gray, Consultant, Inzlingen, Theodor W. Guentert, F. Hoffmann-La Roche AG, Basel, Nick Holford, University of Auckland, Auckland, Hanno Langen, F. Hoffmann - La Roche AG, Basel, Thierry Lavé, F. Hoffmann-La Roche AG, Basel, Christoph Meier, University Hospital, Basel, Armin Meinzer, Novartis Pharma AG, Basel, Urs A. Meyer, Biozentrum, University of Basel, Basel, Andrew Parkinson, XenoTech LLC, Lenexa, Michael Pech, F. Hoffmann - La Roche, Basel, Gérard Pons, Hôpital Saint-Vincent-de-Paul, Paris Cedex 14, John Posner, Consultant, Beckenham, Kent, Ivar Roots, Institut für Klinische Pharmakologie, Berlin, Malcolm Rowland, University of Manchester, Manchester, Rashmi Shah, Independent Pharmaceutical Consultant, Gerrards Cross, Eric Snoeck, Exprimo, Meerhout, Donald Stanski, Novartis Pharma AG, Basel, Frank-Peter Theil, Bayer AG, Wuppertal, Geoffrey T. Tucker, Univesity of Sheffield, Sheffield, John Urquhart, Consultant, Palo Alto, CA, Peter van Brummelen, Van Brummelen Global Drug, CW Hilversum, Jan Willem van der Laan, National Institute of Public Health and the Environment, Bildhoven, Joop van Gerven, Centre for Human Drug Research, CL Leiden, Janet R. Wade, Exprimo NV, Uppsala

Location / venue

Pharmacenter, University of Basel

Costs

ECPM Course incl. six modules 11’500 CHF; for members of the University 4’000 CHF

Timing & Workload

Duration Four days
ECTS points 30 (see remarks)
 

Teaching methods used

Teaching incl. case studies

Examination yes

Criteria

Is the course taught in English? yes
Is documentation available? (book, syllabus)? yes
Is the course open for external researchers? yes

Remarks

This is a Base Module in the ECPM course for post graduates. Costs and ECTS points listed are for the total ECPM master program. The complete program consists of six four-day modules over two years.

More Information

http://www.ecpm.ch